Dr. Jonathan R. Strosberg on 177-Lu-Dotatate in Patients With Neuroendocrine Tumors

Jonathan R. Strosberg, MD

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the targeted, systemic radiation treatment 177-Lu-Dotatate (Lutathera), a somatostatin analogue peptide, in patients with neuroendocrine tumors.

Jonathan R. Strosberg, MD, associate professor, Moffitt Cancer Center, discusses the targeted, systemic radiation treatment 177-Lu-Dotatate (Lutathera), a somatostatin analogue peptide, in patients with neuroendocrine tumors. Strosberg says this targeted therapy is especially useful due to neuroendocrine tumors generally having high-expressing somatostatin expressers.